This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...
2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...
In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...
On Monday, Beam Therapeutics announced that the U.S. FDA had cleared BEAM-101 for clinical evaluation as a treatment for sickle cell disease. BEAM-101...
Some of the best links we picked up around the internet
Verve Therapeutics demonstrates preclinical proof-of-concept with support from Beam Therapeutics
Multiple new deals and developments and new base editor data from Intellia Therapeutics
